Physician profile
Christopher Angelo Sequeira
NPI 1821309410
$5,080.96
in general payments reported to CMS, 2019-2025
53 companies · $1,420 in 2025
The $1,420 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $116 · 2022: $988 · 2023: $1,177 · 2024: $1,249 · 2025: $1,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,771 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,770.99 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $531.70 | 2022-2025 | Reblozyl, Opdualag, Pomalyst |
| Novartis Pharmaceuticals Corporation | $414.86 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $367.68 | 2022-2025 | Enhertu |
| Seagen INC. | $261.73 | 2022-2023 | Adcetris |
| Gilead Sciences, INC. | $260.66 | 2022-2025 | Trodelvy |
| Janssen Biotech, INC. | $238.66 | 2022-2025 | Rybrevant, Darzalex, Erleada |
| Astellas Pharma US INC | $231.42 | 2022-2025 | Padcev, Vyloy, Xospata |
| Daiichi Sankyo INC. | $227.97 | 2020-2025 | Enhertu, Vanflyta |
| Abbvie INC. | $185.47 | 2024-2025 | |
| Pfizer INC. | $180.34 | 2019-2025 | |
| Genentech USA, INC. | $164.98 | 2020-2024 | Alecensa, Tecentriq, Phesgo |
| Merck Sharp & Dohme LLC | $141.74 | 2019-2025 | Keytruda, Lynparza |
| Jazz Pharmaceuticals INC. | $138.78 | 2022-2025 | Zepzelca |
| E.R. Squibb & Sons, L.L.C. | $123.88 | 2019-2025 | Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $94.06 | 2022-2023 | Imbruvica |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $90.97 | 2020-2023 | Lumakras |
| Incyte Corporation | $90.88 | 2022-2025 | Jakafi |
| Genzyme Corporation | $89.41 | 2020-2025 | |
| Lilly USA, LLC | $75.88 | 2023-2024 | Retevmo, Jaypirca, Verzenio |
| Pharmaessentia USA Corporation | $73.06 | 2025 | Besremi |
| Kite Pharma, INC. | $69.93 | 2022-2025 | Yescarta |
| Bayer Healthcare Pharmaceuticals INC. | $68.57 | 2022-2024 | |
| Tersera Therapeutics LLC | $67.83 | 2022-2025 | Zoladex |
| Agios Pharmaceuticals, INC. | $58.43 | 2023-2025 | Pyrukynd |
| Beigene USA, INC. | $56.89 | 2023-2024 | Brukinsa |
| Beone Medicines USA, INC. | $52.79 | 2025 | Brukinsa, Tevimbra |
| Glaxosmithkline, LLC. | $51.86 | 2023-2024 | Ojjaara |
| Eisai INC. | $45.37 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $43.31 | 2022 | |
| Sumitomo Pharma America, INC. | $37.48 | 2024 | Orgovyx |
| Recordati_rare_diseases_inc. | $36.41 | 2025 | Enjaymo |
| Pharmacosmos Therapeutics INC. | $35.71 | 2023 | Monoferric |
| Csl Behring | $34.75 | 2023 | Idelvion, Afstyla |
| Alexion Pharmaceuticals, INC. | $34.21 | 2022-2024 | Ultomiris |
| Array Biopharma INC | $33.88 | 2023-2024 | Braftovi, Mektovi, Lorbrena |
| Myovant Sciences INC. | $33.39 | 2022 | |
| Adc Therapeutics America, INC. | $29.60 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.88 | 2025 | Fruzaqla |
| Napo Pharmaceuticals INC | $26.64 | 2024 | Gelclair Concentrated Oral Gel |
| Aurobindo Pharma USA, INC. | $25.74 | 2019 | |
| Taiho Oncology, INC. | $25.35 | 2023 | |
| Acrotech Biopharma INC. | $21.62 | 2025 | Beleodaq |
| Karyopharm Therapeutics INC. | $21.02 | 2025 | Xpovio |
| Genmab U.S., INC. | $18.33 | 2025 | Epkinly |
| Emd Serono, INC. | $18.19 | 2025 | |
| Cti Biopharma Corp. | $18.07 | 2022 | |
| Deciphera Pharmaceuticals INC. | $17.98 | 2023 | Qinlock |
| Global Blood Therapeutics, INC. | $16.40 | 2022 | |
| Servier Pharmaceuticals LLC | $14.78 | 2024 | |
| Exelixis INC. | $14.74 | 2025 | Cabometyx |
| Stemline Therapeutics INC. | $13.50 | 2023 | Orserdu |
| Sun Pharmaceutical Industries INC. | $13.39 | 2023 | Odomzo, Yonsa |
| Adaptive Biotechnologies Corporation | $11.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Sequeira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.